Earendil Labs, an AI-driven biotechnology company, has announced that it has raised $787 million in funding rounds. PR Newswire has the release.
Earendil’s focus is “advancing next-generation biologics,” and the funding will “accelerate [their] AI-driven R&D program, expand its interdisciplinary teams, and advance a growing pipeline of antibody and biologics programs.” AI is used “across the full life cycle of biologics R&D” at the company, “enabling the systematic generation and progression of differentiated therapeutic programs.”
So far, the company’s AI-native platform “has produced more than 40 programs.” Their focus is on “patients suffering from diseases that still lack effective treatment options.”
The company has partnered with Sanofi for “next-generation biospecific antibodies for autoimmune and inflammatory bowel diseases,” and the companies have also collaborated to “apply [Earendil’s] AI-driven discovery platform to multiple autoimmune and inflammatory disease programs.” Earendil hopes to “scale its AI-driven research and development across biologics discovery and development while expanding its scientific, engineering, and translational teams to support pipeline growth. The capital will also advance multiple internal programs toward clinical milestones and deepen strategic partnerships to accelerate the delivery of innovative biologics to patients globally.”
